Cogimpa, a Webionz.com project by Fidel Olivieri Logo
    • Napredno pretraživanje
  • Gost
    • Prijaviti se
    • Registar
    • Noćni način
emmaverghise Cover Image
User Image
Povucite za promjenu položaja poklopca
emmaverghise Profile Picture
emmaverghise

@emmaverghise

  • Vremenska Crta
  • grupe
  • sviđanja
  • Praćenje
  • Sljedbenici
  • Fotografije
  • Video zapisi
  • Koluti
emmaverghise profile picture emmaverghise profile picture
emmaverghise
13 sati

The U.S. nutrigenomics market reached USD 185.06 million in 2024 and is forecast to grow at a CAGR of 17.6% through 2034, reflecting the field’s entrenched position in mainstream healthcare, wellness, and preventative medicine. While the United States remains the dominant force globally, countries such as China, Germany, and South Korea are playing pivotal roles in shaping the industry’s trajectory. National policy impact, market share concentration, R&D leadership, and strategic positioning are increasingly influential in determining corporate success amid rising global competition and shifting geopolitical dynamics.
In the U.S., federal agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) continue to drive regulatory frameworks that support the scientific validation and clinical adoption of nutrigenomic testing. The Bipartisan Infrastructure Law and recent updates to the 21st Century Cures Act have catalyzed new capital investments from major players like Quest Diagnostics, Thermo Fisher Scientific, and Nutrigenomix, who are expanding testing capacities and integrating AI-based interpretation tools. Strategic acquisitions—such as LabCorp’s acquisition of Personalized Nutrition and ZOE’s partnership with King’s College London—are consolidating market share and reinforcing the dominance of established players in both research and commercialization phases.
China has emerged as a formidable contender, with state-backed programs like the Precision Medicine Initiative and Made in China 2025 strategy supporting domestic innovation in nutrigenomics. BGI Genomics and Wuxi AppTec are aggressively scaling up their capabilities in population genetics and bioinformatics, often partnering with Western diagnostics firms to access global markets. Trade policies and export controls, however, remain a source of uncertainty, prompting some multinational corporations to diversify their supply chains and establish satellite labs in Southeast Asia.
Read More @ https://www.polarismarketresea....rch.com/industry-ana
Germany stands out for its methodical approach to nutrigenomics, characterized by strong collaboration between academia, industry, and regulatory bodies. The Max Planck Institute and University Hospital Heidelberg play instrumental roles in translating basic research into commercial applications, while companies like Qiagen and Eurofins Genomics are investing heavily in next-generation sequencing platforms and proprietary SNP databases. The country’s emphasis on quality control and process standardization makes it a preferred location for setting up centralized testing laboratories catering to European and global clients.
Corporate strategies among top-tier players are increasingly centered around geographic expansion, vertical integration, and technology leadership. Major firms are not only acquiring boutique analytics shops but also building internal capabilities in machine learning, digital therapeutics, and remote patient monitoring to enhance system reliability and customer satisfaction. Market share concentration remains moderate, with the top five companies accounting for approximately 57% of total revenue, although niche players specializing in specific disease pathways or ethnic populations are gaining traction in targeted therapeutic areas.
R&D leadership is concentrated among a few dominant players who invest heavily in multi-omics integration, population-specific biomarkers, and AI-enhanced dietary modeling designed to improve clinical relevance and scalability. Strategic positioning is also influenced by patent portfolios and participation in international consortia, which provide leverage in licensing negotiations and market access discussions. As the nutrigenomics market matures, companies that align their innovation pipelines with macroeconomic shifts and policy imperatives will be best positioned to capitalize on the long-term tailwinds shaping the future of personalized nutrition.
Dominant Players by Market Share:
• Nutrigenomix Inc.
• DNAfit Ltd.
• Pathway Genomics Corporation
• Quest Diagnostics Incorporated
• BGI Genomics Co., Ltd.
• Thermo Fisher Scientific Inc.
• MyDNA Life Inc.
• ZOE Inc.
More Trending Latest Reports By Polaris Market Research:
Cladding Systems Market
Robot Charging Station Market
Ultrasonic Air Bubble Detectors Market
Healthcare It Market
Tiki Torch Market
Healthy Snacks Market
Lipid Regulators Market
Superfoods Market
Electric Kick Scooters Market

U.S. Nutrigenomics Market Size, Value & Share Analysis [2034]
www.polarismarketresearch.com

U.S. Nutrigenomics Market Size, Value & Share Analysis [2034]

U.S. Nutrigenomics Market in terms of revenue was estimated to be worth USD 185.06 million in 2024 and exhibiting a CAGR of 17.6% by 2034
Kao
Komentar
Udio
emmaverghise profile picture emmaverghise profile picture
emmaverghise promijenila profilnu sliku
13 sati

image
Kao
Komentar
Udio
 Učitaj još postova
    Info
    • Žena
    • postovi 2
    Albumi 
    (0)
    Praćenje 
    (0)
    Sljedbenici 
    (2)
    sviđanja 
    (0)
    grupe 
    (0)

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

Jezik

  • Oko
  • Imenik
  • Blog
  • Kontaktirajte nas
  • Programeri
  • Više
    • Politika privatnosti
    • Uvjeti korištenja
    • Zatražite povrat novca

Ukini prijateljstvo

Jeste li sigurni da želite prekinuti prijateljstvo?

Prijavi ovog korisnika

Važno!

Jeste li sigurni da želite ukloniti ovog člana iz svoje obitelji?

Bockali ste Emmaverghise

Novi član je uspješno dodan na vaš obiteljski popis!

Izrežite svoj avatar

avatar

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

  • Dom
  • Oko
  • Kontaktirajte nas
  • Politika privatnosti
  • Uvjeti korištenja
  • Zatražite povrat novca
  • Blog
  • Programeri
  • Jezik

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

  • Dom
  • Oko
  • Kontaktirajte nas
  • Politika privatnosti
  • Uvjeti korištenja
  • Zatražite povrat novca
  • Blog
  • Programeri
  • Jezik

Komentar je uspješno prijavljen.

Objava je uspješno dodana na vašu vremensku traku!

Dosegli ste ograničenje od 5000 prijatelja!

Pogreška veličine datoteke: datoteka premašuje dopušteno ograničenje (92 MB) i ne može se učitati.

Vaš se videozapis obrađuje. Obavijestit ćemo vas kada bude spreman za gledanje.

Nije moguće učitati datoteku: ova vrsta datoteke nije podržana.

Otkrili smo sadržaj za odrasle na slici koju ste prenijeli, stoga smo odbili vaš postupak učitavanja.

Podijelite objavu u grupi

Podijelite na stranicu

Podijeli s korisnikom

Vaš je post poslan, uskoro ćemo pregledati vaš sadržaj.

Za prijenos slika, videozapisa i audio datoteka morate nadograditi na pro člana. Nadogradi na pro

Uredi ponudu

0%

Dodajte razinu








Odaberite sliku
Izbrišite svoju razinu
Jeste li sigurni da želite izbrisati ovu razinu?

Recenzije

Kako biste prodali svoj sadržaj i postove, počnite s stvaranjem nekoliko paketa. Monetizacija

Plaćanje novčanikom

Dodaj paket

Izbriši svoju adresu

Jeste li sigurni da želite izbrisati ovu adresu?

Uklonite svoj paket monetizacije

Jeste li sigurni da želite izbrisati ovaj paket?

Odjavi pretplatu

Jeste li sigurni da želite otkazati pretplatu na ovog korisnika? Imajte na umu da nećete moći vidjeti njihov unovčeni sadržaj.

Upozorenje o plaćanju

Spremate se kupiti artikle, želite li nastaviti?
Zatražite povrat novca

Jezik

  • Arabic
  • Bengali
  • Chinese
  • Croatian
  • Danish
  • Dutch
  • English
  • Filipino
  • French
  • German
  • Hebrew
  • Hindi
  • Indonesian
  • Italian
  • Japanese
  • Korean
  • Persian
  • Portuguese
  • Russian
  • Spanish
  • Swedish
  • Turkish
  • Urdu
  • Vietnamese